Background and Objective: Thyroid-associated ophthalmopathy (TAO) is the most common
extrathyroidal manifestation of Graves disease, occasionally severe and refractory to treatment, mainly
in long-term disease. In these cases, one of the most important infiltrating cytokines in the orbital tissue
is interleukin-6 (IL-6).
Methods: This is a case report, the methodology consisted of the application of tocilizumab in a patient
with graves disease and the patient's follow-up.
Results: We present the case of a 54-year-old male with TAO who responded adequately to treatment
with tocilizumab, an antibody directed against the IL-6 receptor.
Conclusion: Tocilizumab could be an optional treatment in patients with TAO.